Tian Fang, Zhang Xiongwen, Tong Yunguang, Yi Yanghua, Zhang Shilong, Li Ling, Sun Peng, Lin Liping, Ding Jian
Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Science, Chinese Academy of Sciences, PR China.
Cancer Biol Ther. 2005 Aug;4(8):874-82. doi: 10.4161/cbt.4.8.1917.
Here, we examined the in vitro and in vivo anti-angiogenesis and anti-tumor activities of PE, a new marine-derived compound. Inhibition of angiogenesis was assessed in vitro using proliferation, migration, adhesion, tube-formation and apoptosis assays in PE-treated HMECs and HUVECs. In vivo, CAM assays were used to assess inhibition effect of PE on physiological angiogenesis, and immunofluorescent microscopy was used to examine tumor microvessel density and apoptosis in PE-treated mouse tumor models. Finally, Western blotting analyses were performed to examine the effect of PE on VEGF signaling in HMECs. The results showed that PE inhibited proliferation of HMECs and HUVECs with IC50 values of 2.22 +/- 0.31 microM and 1.98 +/- 0.32 microM, induced endothelial cell apoptosis at concentrations <2 microM, induced dose-dependent suppression of cell migration, cell adhesion and tube formation in HMECs and HUVECs, and showed anti-proliferative activities against several tumor cell lines (IC50 values of approximately 4 microM). In vivo, PE (5 nM/egg) suppressed spontaneous angiogenesis in our CAM assay, and induced marked growth inhibition in mouse sarcoma 180 and hepatoma 22 models. Specifically, PE treatment reduced mouse sarcoma 180 tumor volume by triggering apoptosis of both tumor and tumor-associated endothelial cells, preferentially targeting on endothelial cells comparable with tumor cells. Finally, PE treatment suppressed the active (phosphorylated) forms of VEGFR2, Akt, ERK, FAK and paxillin, which are involved in endothelial cell survival, proliferation, adhesion and migration. Our results indicate that PE exerts an anti-angiogenic activity associated with inhibition of VEGFR2 signaling, and an anti-tumor activity associated with decreased proliferation of tumor cells and increased apoptosis of both endothelial cells and tumor cells.
在此,我们研究了一种新的海洋来源化合物PE的体外和体内抗血管生成及抗肿瘤活性。在体外,通过对经PE处理的人微血管内皮细胞(HMECs)和人脐静脉内皮细胞(HUVECs)进行增殖、迁移、黏附、管腔形成和凋亡检测来评估血管生成的抑制情况。在体内,采用鸡胚绒毛尿囊膜(CAM)试验评估PE对生理性血管生成的抑制作用,并利用免疫荧光显微镜检查经PE处理的小鼠肿瘤模型中的肿瘤微血管密度和凋亡情况。最后,进行蛋白质印迹分析以检测PE对HMECs中血管内皮生长因子(VEGF)信号传导的影响。结果显示,PE抑制HMECs和HUVECs的增殖,IC50值分别为2.22±0.31微摩尔/升和1.98±0.32微摩尔/升,在浓度<2微摩尔/升时诱导内皮细胞凋亡,在HMECs和HUVECs中诱导剂量依赖性的细胞迁移、细胞黏附和管腔形成抑制,并对几种肿瘤细胞系表现出抗增殖活性(IC50值约为4微摩尔/升)。在体内,PE(5纳摩尔/枚鸡蛋)在我们的CAM试验中抑制了自发血管生成,并在小鼠肉瘤180和肝癌22模型中诱导了显著的生长抑制。具体而言,PE处理通过触发肿瘤细胞和肿瘤相关内皮细胞的凋亡来减少小鼠肉瘤180的肿瘤体积,与肿瘤细胞相比,优先靶向内皮细胞。最后,PE处理抑制了参与内皮细胞存活、增殖、黏附和迁移的VEGFR2、Akt、ERK、FAK和桩蛋白的活性(磷酸化)形式。我们的结果表明,PE发挥了与抑制VEGFR2信号传导相关的抗血管生成活性,以及与肿瘤细胞增殖减少和内皮细胞及肿瘤细胞凋亡增加相关的抗肿瘤活性。